Join PDS Biotechnology for a virtual Key Opinion Leader (KOL) event to discuss positive, updated data from its VERSATILE-002 Phase 2 clinical trial, current unmet need in HPV-positive head and neck cancer, and next steps for PDS Biotech’s planned triple combination trial including Versamune^® HPV and PDS01ADC (IL-12 fused antibody drug conjugate).

Panel participants will include:

• Jared Weiss, MD, Section Chief of Thoracic and Head/Neck Oncology, Professor of Medicine at University of North Carolina, and Principal Investigator of the VERSATILE-002 clinical trial, who will present and discuss the updated trial results
• Robert Haddad, MD, Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute, who will discuss the unmet need in HPV-positive head and neck squamous cell cancer (“HNSCC”)

The VERSATILE-002 trial (NCT04260126) is evaluating Versamune^® HPV in combination with the immune checkpoint inhibitor (“ICI”) KEYTRUDA^® (pembrolizumab) in patients with unresectable, recurrent, or metastatic HPV16-positive HNSCC.

A live Q&A session will follow the formal presentations.